central and peripheral glp 1 systems independently suppress eating An inter-organ neural circuit for appetite suppression Frontiers | The central GLP-1:
Description
Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to a late-stage trial

No, topiramate is not a GLP-1 medication

SU = sulfonylurea

One Epic Experience

One GLP-1 drug worked only briefly

The weight effects of GLP-1 therapy are potentially significant for the treatment of T2D, in which excessive caloric intake and weight management are important issues that are difficult to control
